- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01959984
Study on the Comparison Between"Standard Noodles" and Traditional Carbohydrates in the Diagnosis of Diabetes Mellitus.
The object of this study is to compare "100g Standard Noodles " with traditional carbohydrates including 75g glucose solution in 300ml water and 100g steamed bread in the diagnosis of diabetes mellitus.
In this study, we will compare the different effects of "100g Standard Noodles Tolerance Test"and "75g Oral Glucose Tolerance Test"on plasma glucose, insulin, c- peptide level and the relevant hormones level including glucagon-like peptide-1( GLP-1) and glucagon. Besides, in part of the subjects, the difference between "100g Steamed Bread Tolerance Test", "100g Standard Noodles Tolerance Test" and "75g Oral Glucose Tolerance Test" will be further evaluated.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Förväntat)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Shanghai
-
Shanghai, Shanghai, Kina, 200021
- Shanghai Jiao Tong University School of Medicine
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Inclusion Criteria:
For healthy subjects:
- Between 16-70 years old.
- No weight fluctuation greater than 5% within 3 months.
- Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures .
For subjects with impaired glucose regulation(IGR):
- Between 16-70 years old.
- Impaired fasting glucose(IFG):6.1mM(109mg/ml)≤fasting plasma glucose(FPG)<7.0mM(126mg/ml),or impaired glucose tolerance(IGT):7.8mM(140mg/ml)≤2h plasma glucose(2hPG)<11.1mM(200mg/dl),or both.
- No weight fluctuation greater than 5% within3 months.
- Keep stable antidiabetic therapy for at least 2 months.
- Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures .
For subjects with type 2 diabetes mellitus(T2DM):
- Between 16-70 years old.
- T2DM:diabetic symptoms plus random blood glucose(RBG)≥11.1mM,or FPG ≥7.0mM(126mg/dl),or 2hPG ≥11.1mM(200mg/dl).
- No weight fluctuation greater than 5% within 3 months.
- Keep stable antidiabetic therapy at least for 2 months.
- Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures.
For subjects with type 1 diabetes mellitus(T1DM):
- Between 16-70 years old.
- T1DM:diabetic symptoms plus RBG≥11.1mM,or FPG ≥7.0mM(126mg/dl),or 2hPG ≥11.1mM(200mg/dl).
- Present at least one positive antibody of β cell including ICA,IAA,GADA,IA-2A and IA-2βA.
- No weight fluctuation greater than 5% within 3 months.
- Keep stable antidiabetic therapy for at least 2 months.
- Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures.
Exclusion Criteria:
For healthy subjects:
- Be diagnosed with diabetes or IGR in late 3 months.
- With any significant medical condition,laboratory abnormality,or psychiatric disorders that will prevent the subject from participating in the study.
- Any medical or surgical conditions possibly affecting the experiment result.
- Participated in a clinical study involving administration of medication within 90 days.
- Donated blood or plasma or had any other significant blood loss within 2 months.
- Any clinically significant allergic diseases.
- Recently drug or alcohol abuse(>35unit/week,1unit=8 g alcohol@1 standard drink@250ml beer@140ml wine@25ml strong alcohol drink like whiskey.)
- Smokers or users of other tobacco products in the 3 months prior to screening.
For IGR and DM:
- History of pancreatic diseases such as pancreatic cancer or pancreatitis.
- Suffered from acute complications such as diabetic ketoacidosis and hyperosmolar coma within 3 months.
- With any significant medical condition,laboratory abnormality,or psychiatric disorders that will prevent the subject from participating in the study.
- Malignant tumor.
- Being allergic to experiment arms.
- Recently drug or alcohol abuse(>35unit/week,1unit=8 g alcohol@1 standard drink@250ml beer@140ml wine@25ml strong alcohol drink like whiskey.)
Studieplan
Hur är studien utformad?
Designdetaljer
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: 100g Standard Noodles
|
Subjects are required to take 100g standard noodles,and then blood samples are collected at 0min,30min,60min,120min,180min.
|
Experimentell: 75g Oral Glucose
|
Subjects are required to take 75g glucose solution,and then blood samples are collected at 0min,30min,60min,120min,180min.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
The plasma glucose level.
Tidsram: 12 months
|
The primary outcome measures the plasma glucose level at 0min,30min,60min,120min,180min during "75g Oral Glucose Tolerance Test" and "100g Standard Noodles Tolerance Test" .
|
12 months
|
The insulin level.
Tidsram: 12 months
|
The primary outcome measures the insulin level at 0min,30min,60min,120min,180min during "75g Oral Glucose Tolerance Test" and "100g Standard Noodles Tolerance Test" .
|
12 months
|
The c-peptide level.
Tidsram: 12 months
|
The primary outcome measures the c-peptide level at 0min,30min,60min,120min,180min during "75g Oral Glucose Tolerance Test" and "100g Standard Noodles Tolerance Test" .
|
12 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
The GLP-1 level.
Tidsram: 12months
|
The outcome measures of the GLP-1 level at 0min,30min,60min,120min,180min during "75g Oral Glucose Tolerance Test" and "100g Standard Noodles Tolerance Test" .
|
12months
|
The Glucagon level.
Tidsram: 12 months
|
The outcome measures of the glucagon level at 0min,30min,60min,120min,180min during "75g Oral Glucose Tolerance Test" and "100g Standard Noodles Tolerance Test" .
|
12 months
|
The other relevant incretin hormones levels.
Tidsram: 12 months
|
The outcome measures of the relevant incretin hormones level at 0min,30min,60min,120min,180min during "75g Oral Glucose Tolerance Test" and "100g Standard Noodles Tolerance Test" .
|
12 months
|
The plasma glucose, insulin, c-peptide and relevant incretin hormones level during "75g Oral Glucose Tolerance Test", "100g Standard Noodles Tolerance Test" and "100g Steamed Bread Tolerance Test".
Tidsram: 12 months
|
12 months
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Safety
Tidsram: 12 months
|
Document the frequency and extent of side-effects.
|
12 months
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Guang Ning, MD,PHD, Shanghai Jiao Tong University School of Medicine
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CCEMD018
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på 100g Standard Noodles
-
University of ArkansasUniversity of IowaHar inte rekryterat ännuPlasmacellstörning
-
Tampere University HospitalOrion Corporation, Orion PharmaAktiv, inte rekryterande
-
Abant Izzet Baysal UniversityAvslutadPåverkad tredje molar tandKalkon
-
University of PennsylvaniaRestaurant AssociatesAktiv, inte rekryterandeFetma | Viktökning | Matpreferenser | Mat urvalFörenta staterna
-
Corporal Michael J. Crescenz VA Medical CenterAvslutadIdiopatisk lungfibros | KOL | Hjärtsvikt | Malignitet | Allvarlig eller mycket allvarlig luftflödeshinder och/eller ta emot eller kvalificerad att få långvarig syrgasbehandling | Annan interstitiell lungsjukdom utan botande terapi | NYHA klass IV eller NYHA klass III Plus 1 sjukhusvistelse under... och andra villkorFörenta staterna
-
University Hospital, BordeauxInstitut National de la Santé Et de la Recherche Médicale, France; Université... och andra samarbetspartnersAvslutadAlzheimers sjukdomFrankrike
-
Yonsei UniversityRekryteringÅterkommande epitelial äggstockscancerKorea, Republiken av
-
Nantes University HospitalMinistry of Health, France; University Hospital, ToursAvslutadChock | Kritisk sjukdom | Kritisk sjukdom Myopati | Mekanisk ventilation | Nosokomial infektionFrankrike, Guadeloupe
-
Helios Health Institute GmbHHeart Center Leipzig - University HospitalRekryteringST Elevation hjärtinfarktÖsterrike, Tyskland